Institution
Istanbul University
Education•Istanbul, Turkey•
About: Istanbul University is a education organization based out in Istanbul, Turkey. It is known for research contribution in the topics: Population & Medicine. The organization has 19050 authors who have published 38464 publications receiving 727640 citations. The organization is also known as: İstanbul Üniversitesi & University of Istanbul.
Topics: Population, Medicine, Cancer, Breast cancer, Diabetes mellitus
Papers published on a yearly basis
Papers
More filters
••
Institut Gustave Roussy1, Emory University2, Istanbul University3, Kyoto University4, Peking Union Medical College5, University of Texas at San Antonio6, Georgetown University7, Brighton Hospital8, Shanghai Jiao Tong University9, University of Texas MD Anderson Cancer Center10, Novartis11, Vita-Salute San Raffaele University12
TL;DR: The addition of everolimus to trastuzumab-resistant and taxane-pretreated, HER2-positive, advanced breast cancer patients significantly prolongs PFS by local assessment in the intention-to-treat population.
Abstract: Summary Background Disease progression in patients with HER2-positive breast cancer receiving trastuzumab might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. We aimed to assess whether the addition of the mTOR inhibitor everolimus to trastuzumab might restore sensitivity to trastuzumab. Methods In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited women with HER2-positive, trastuzumab-resistant, advanced breast carcinoma who had previously received taxane therapy. Eligible patients were randomly assigned (1:1) using a central patient screening and randomisation system to daily everolimus (5 mg/day) plus weekly trastuzumab (2 mg/kg) and vinorelbine (25 mg/m 2 ) or to placebo plus trastuzumab plus vinorelbine, in 3-week cycles, stratified by previous lapatinib use. The primary endpoint was progression-free survival (PFS) by local assessment in the intention-to-treat population. We report the final analysis for PFS; overall survival follow-up is still in progress. This trial is registered with ClinicalTrials.gov, number NCT01007942. Findings Between Oct 26, 2009, and May 23, 2012, 569 patients were randomly assigned to everolimus (n=284) or placebo (n=285). Median follow-up at the time of analysis was 20·2 months (IQR 15·0–27·1). Median PFS was 7·00 months (95% CI 6·74–8·18) with everolimus and 5·78 months (5·49–6·90) with placebo (hazard ratio 0·78 [95% CI 0·65–0·95]; p=0·0067). The most common grade 3–4 adverse events were neutropenia (204 [73%] of 280 patients in the everolimus group vs 175 [62%] of 282 patients in the placebo group), leucopenia (106 [38%] vs 82 [29%]), anaemia (53 [19%] vs 17 [6%]), febrile neutropenia (44 [16%] vs ten [4%]), stomatitis (37 [13%] vs four [1%]), and fatigue (34 [12%] vs 11 [4%]). Serious adverse events were reported in 117 (42%) patients in the everolimus group and 55 (20%) in the placebo group; two on-treatment deaths due to adverse events occurred in each group. Interpretation The addition of everolimus to trastuzumab plus vinorelbine significantly prolongs PFS in patients with trastuzumab-resistant and taxane-pretreated, HER2-positive, advanced breast cancer. The clinical benefit should be considered in the context of the adverse event profile in this population. Funding Novartis Pharmaceuticals Corporation.
433 citations
••
TL;DR: The aim of this chapter is to explain endothelial dysfunction and the circulating molecules of endothelial cells as they become potential targets of therapeutic approach for hypertension, and the role of endothelium dysfunction in white coat hypertension has been discussed.
Abstract: In the past, endothelium was thought to be only a mechanical barrier. Today, endothelium is known to be a tissue regulating vascular tone, cell growth and the interaction between the leukocytes, thrombocytes and the vessel wall. It also synthesizes growth factors and thrombo-regulatory molecules and responds to physical and chemical signals. Even though the term "endothelial dysfunction" is generally used for deterioration of endothelium-dependent vasodilatation; the term also includes the abnormalities between endothelium and leukocytes, thrombocytes and regulatory molecules and conditions resulting in aberrant endothelium activation. Healthy endothelium is essential for cardiovascular control. Thus, it plays an important role in pathogenesis of many diseases and cardiovascular problems such as atherosclerosis, systemic and pulmonary hypertension, cardiomyopathies and vasculitides. The aim of this chapter is to explain endothelial dysfunction and the circulating molecules of endothelial cells as they become potential targets of therapeutic approach for hypertension. This chapter reviews the roles of endothelial dysfunction in hypertension by addressing (1) the nature of endothelial function, (2) mechanisms of endothelial dysfunction and its relationship with the diseases (3) also endothelial function testing (4) the role of endothelial dysfunction and hypertension and (4) the effects of antihypertensive therapeutic options on the endothelial dysfunction. In addition to these, the role of endothelial dysfunction in white coat hypertension has been discussed. The key connections between hypertension and endothelial dysfunction are vitally important for future studies to permit new interventions to be designed and released.
432 citations
••
TL;DR: In this paper, the effect of the adsorbent concentration on the adsorption was studied and the dependence of the adaption of fluoride on the pH of the solution has been studied to achieve the optimum pH-value.
431 citations
••
Lamont–Doherty Earth Observatory1, University of East Anglia2, University of Freiburg3, Royal Netherlands Meteorological Institute4, Queen's University Belfast5, University of Padua6, University of Ljubljana7, University of Mainz8, Cornell University9, Stockholm University10, Dresden University of Technology11, University of Barcelona12, United States Department of State13, Deutsches Archäologisches Institut14, Czech University of Life Sciences Prague15, Istanbul University16, University of Gothenburg17, University of Oxford18, University of Pavia19, University of Forestry, Sofia20, Norwegian University of Science and Technology21, University of Arizona22, Nicolaus Copernicus University in Toruń23, University of St Andrews24, Technische Universität München25
TL;DR: Megadroughts reconstructed over north-central Europe in the 11th and mid-15th centuries reinforce other evidence from North America and Asia that droughts were more severe, extensive, and prolonged over Northern Hemisphere land areas before the 20th century, with an inadequate understanding of their causes.
Abstract: Climate model projections suggest widespread drying in the Mediterranean Basin and wetting in Fennoscandia in the coming decades largely as a consequence of greenhouse gas forcing of climate. To place these and other “Old World” climate projections into historical perspective based on more complete estimates of natural hydroclimatic variability, we have developed the “Old World Drought Atlas” (OWDA), a set of year-to-year maps of tree-ring reconstructed summer wetness and dryness over Europe and the Mediterranean Basin during the Common Era. The OWDA matches historical accounts of severe drought and wetness with a spatial completeness not previously available. In addition, megadroughts reconstructed over north-central Europe in the 11th and mid-15th centuries reinforce other evidence from North America and Asia that droughts were more severe, extensive, and prolonged over Northern Hemisphere land areas before the 20th century, with an inadequate understanding of their causes. The OWDA provides new data to determine the causes of Old World drought and wetness and attribute past climate variability to forced and/or internal variability.
429 citations
••
University of Cambridge1, University of Glasgow2, University of Washington3, Uppsala University4, Harvard University5, Ludwig Maximilian University of Munich6, Centers for Disease Control and Prevention7, French Institute of Health and Medical Research8, Innsbruck Medical University9, University of Ulm10, Boston University11, University College London12, Wageningen University and Research Centre13, Istanbul University14, Merck & Co.15, University of Gothenburg16, Medical University of South Carolina17, Cardiff University18, Erasmus University Rotterdam19, University of Pavia20, University of California, San Diego21, University of Oxford22, University of New South Wales23, University of the East24, University of Copenhagen25, University of Amsterdam26, University of Iceland27
TL;DR: In a study of individuals without known CVD, the addition of information on the combination of apolipoprotein B and A-I, lipop protein(a), or lipoprotein-associated phospholipase A2 mass to risk scores containing total cholesterol and HDL-C led to slight improvement in CVD prediction.
Abstract: ContextThe value of assessing various emerging lipid-related markers for prediction of first cardiovascular events is debated.Objective To determine whether adding information on apolipoprotein B a ...
429 citations
Authors
Showing all 19361 results
Name | H-index | Papers | Citations |
---|---|---|---|
Bobby Samir Acharya | 133 | 1121 | 100545 |
Serkant Ali Cetin | 129 | 1369 | 85175 |
Alexander Nikitenko | 129 | 1159 | 82102 |
Aytul Adiguzel | 124 | 964 | 71366 |
Neil Risch | 122 | 386 | 70042 |
Laurent Poirel | 117 | 621 | 53680 |
Andrei Starodumov | 114 | 697 | 57900 |
Suat Ozkorucuklu | 110 | 698 | 55607 |
Robert J. Desnick | 102 | 694 | 39698 |
Lars Berglund | 97 | 641 | 42300 |
Angel Carracedo | 88 | 885 | 38053 |
Peter A. Merkel | 85 | 430 | 34014 |
Thomas A. Pearson | 84 | 349 | 41573 |
Willy Malaisse | 80 | 1635 | 31641 |
C. Pagliarone | 79 | 796 | 27164 |